Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its target price lowered by Stifel Nicolaus from $22.00 to $19.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus‘s price target would indicate a potential upside of 126.46% from the company’s current price.
A number of other research firms have also weighed in on CADL. Jefferies Financial Group started coverage on shares of Candel Therapeutics in a research report on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price objective on the stock. Zacks Research downgraded shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Bank of America upgraded Candel Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $12.00 to $18.00 in a research report on Monday, September 21st. Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Candel Therapeutics in a research note on Friday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.
Get Our Latest Stock Analysis on CADL
Candel Therapeutics Trading Down 9.0%
CADL stock opened at $8.39 on Friday. Candel Therapeutics has a twelve month low of $4.35 and a twelve month high of $14.00. The stock has a market capitalization of $642.00 million, a price-to-earnings ratio of -5.95 and a beta of -0.27. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38. The firm’s fifty day simple moving average is $9.89 and its two-hundred day simple moving average is $8.39.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. As a group, analysts anticipate that Candel Therapeutics will post -1.29 earnings per share for the current year.
Insider Buying and Selling
In related news, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $12.00, for a total transaction of $84,000.00. Following the completion of the sale, the chief technology officer owned 76,865 shares in the company, valued at $922,380. This trade represents a 8.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 14.30% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Candel Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Candel Therapeutics during the second quarter worth approximately $51,181,000. Bank of America Corp DE bought a new stake in shares of Candel Therapeutics during the second quarter valued at approximately $2,873,000. Wellington Management Group LLP bought a new stake in shares of Candel Therapeutics during the second quarter valued at approximately $2,119,000. Bank of New York Mellon Corp purchased a new stake in shares of Candel Therapeutics in the second quarter valued at approximately $1,975,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Candel Therapeutics in the first quarter valued at approximately $845,000. 13.93% of the stock is currently owned by institutional investors.
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Further Reading
- Five stocks we like better than Candel Therapeutics
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
